results of hepatitis c virus (hcv) treatment program among...
TRANSCRIPT
![Page 1: RESULTS OF HEPATITIS C VIRUS (HCV) TREATMENT PROGRAM AMONG …regist2.virology-education.com/presentations/3... · In 2016 among new cases of HIV-infection (n=14 334) Viral Hepatitis](https://reader031.vdocuments.site/reader031/viewer/2022011912/5fa5eed0ef2ee675b9528dff/html5/thumbnails/1.jpg)
www.aph.org.ua
RESULTS OF HEPATITIS C VIRUS (HCV) TREATMENT PROGRAM AMONG PEOPLE WHO INJECT DRUGS (PWID) WITH HIV/HCV CO-INFECTION
Sergii Filippovych,
Director: Treatment, Procurement
and Supply Management
![Page 2: RESULTS OF HEPATITIS C VIRUS (HCV) TREATMENT PROGRAM AMONG …regist2.virology-education.com/presentations/3... · In 2016 among new cases of HIV-infection (n=14 334) Viral Hepatitis](https://reader031.vdocuments.site/reader031/viewer/2022011912/5fa5eed0ef2ee675b9528dff/html5/thumbnails/2.jpg)
www.aph.org.ua
Ukraine: Epidemiological Background
Population: 42 590 879 million
❖ WHO estimates 3% of HCV prevalence in Ukraine (1 280 000)
❖ According to official web of the Cabinet of Ministers of Ukraine national epidemiologists estimate HCV
prevalence in Ukraine at around 7-9% of general population (2 980 000-3 830 000 individuals)
❖ According to the Center of Medical Statistics of the Ministry of Health of Ukraine number of HCV patients in
2016 reached 46 883
❖ In 2016 among new cases of HIV-infection (n=14 334) Viral Hepatitis C Markers were detected in 21.5% of
cases (n=3080)
❖ 30 826 persons were HIV/HVC co-infected as of January 1st, 2017
❖ HCV prevalence rate among PWID in Ukraine exceeds overall average, reaching 56% (2015, Alliance bio-
behavioral research)
❖ Estimated number of PWID in Ukraine is 346 900
❖ Estimated number of PLWH 238 000
![Page 3: RESULTS OF HEPATITIS C VIRUS (HCV) TREATMENT PROGRAM AMONG …regist2.virology-education.com/presentations/3... · In 2016 among new cases of HIV-infection (n=14 334) Viral Hepatitis](https://reader031.vdocuments.site/reader031/viewer/2022011912/5fa5eed0ef2ee675b9528dff/html5/thumbnails/3.jpg)
www.aph.org.ua
Scaling up Accessible and Effective HCV Treatment through Community-Based Treatment Model for Key Populations in Resource Constrained Ukraine
Key populations: PWID, OST patients, CSW, MSM
Enrollment criteria: Fibrosis≥ F2 (priority F3, F4), METAVIR
Implementation of community-supported DAAs-based HCV treatment model for key populations
Access to laboratory diagnostics (treatment monitoring and follow-up)
Operational research “Effectiveness of HCV Treatment Program for MARPs in the Resource Constrained Ukraine”
Project key objectives:
![Page 4: RESULTS OF HEPATITIS C VIRUS (HCV) TREATMENT PROGRAM AMONG …regist2.virology-education.com/presentations/3... · In 2016 among new cases of HIV-infection (n=14 334) Viral Hepatitis](https://reader031.vdocuments.site/reader031/viewer/2022011912/5fa5eed0ef2ee675b9528dff/html5/thumbnails/4.jpg)
www.aph.org.ua
Scaling up Accessible and Effective HCV Treatment through Community-Based
Treatment Model for Key Populations in Resource Constrained Ukraine
Project period: April 2015 – December 2017
Geographic coverage: starting from 8 healthcare facilities in 7 regions of Ukraine the Project has expanded for
25 medical settings in 19 oblasts of Ukraine
![Page 5: RESULTS OF HEPATITIS C VIRUS (HCV) TREATMENT PROGRAM AMONG …regist2.virology-education.com/presentations/3... · In 2016 among new cases of HIV-infection (n=14 334) Viral Hepatitis](https://reader031.vdocuments.site/reader031/viewer/2022011912/5fa5eed0ef2ee675b9528dff/html5/thumbnails/5.jpg)
www.aph.org.uawww.aph.org.ua
0 200 400 600 800 1000 1200 1400 1600 1800 2000
Treatment completion,PWID (n=1512)
PWID (n=1512)
Of them on ART
Of them HCV/HIVco-infected
Enrolled on treatment,by GT (n=1884)
Enrolled on treatment,by Fibrosis (n=1884)
Completed full treatment course (n=1337)
1348
1352
1392
GT1 (n=1029; 54.3%)
F1 (n=104; 5.5%)
Continue treatment (n=151)
PWID on OST (n=164)
GT2 (n=79; 4.2%)
F2 (b=881; 46.8%)
Terminated treatment
(n=24; 1.6%)
GT3 (n=759; 40.6%)
F3 (n=493; 26.2%)
GT4 (n=9; 0.5%)
F4 (n=406; 21.5%)
GT mixed or untypable
(n=8; 0.4%)
Number of patients
74.4%
97.1%80.2%
HCV Treatment Project: Deliverables as of Aug, 1st, 2017
![Page 6: RESULTS OF HEPATITIS C VIRUS (HCV) TREATMENT PROGRAM AMONG …regist2.virology-education.com/presentations/3... · In 2016 among new cases of HIV-infection (n=14 334) Viral Hepatitis](https://reader031.vdocuments.site/reader031/viewer/2022011912/5fa5eed0ef2ee675b9528dff/html5/thumbnails/6.jpg)
www.aph.org.ua
HCV Treatment Project: PWID Cohort Data*
Cohort Date (n=937), patients (%)
Male 750 (80.0%)
Median age, years 39
HIV co-infection 748 (79.8%)
• out of them receive ART 728 (97.3%)
HBV co-infection 96 (10.2%)
PWID on OST 88 (9.4%)
Treatment Regimens among PWID, patients
SOF+Peg-IFN+RBV 12W 687
SOF+RBV 12W 39
SOF+RBV 16W 4
SOF+RBV 24W 176
SOF+DCV 12-24W 30
SOF/LDV 12W 1
* Cohort includes only PWID patients who received HCV VL evaluation at W12 after finishing full treatment course or terminated treatment.
![Page 7: RESULTS OF HEPATITIS C VIRUS (HCV) TREATMENT PROGRAM AMONG …regist2.virology-education.com/presentations/3... · In 2016 among new cases of HIV-infection (n=14 334) Viral Hepatitis](https://reader031.vdocuments.site/reader031/viewer/2022011912/5fa5eed0ef2ee675b9528dff/html5/thumbnails/7.jpg)
www.aph.org.uawww.aph.org.ua
Treatment success among PWID*
93.90%95.70%
90.20% 91.30%
98.30%100.00%
50.00%
55.00%
60.00%
65.00%
70.00%
75.00%
80.00%
85.00%
90.00%
95.00%
100.00%
HCV/HIV coinfected HCV monoinfected
SVR12 rates
PWID in remission Active PWID PWID on OST
* Please note, that HCV VL at W12 after treatment was yet tested only at patients, who received SOF+Peg-IFN+RBV 12W or SOF+RBV 12-24W
(depending on HCV GT and Fibrosis stage) treatment regimens, as patients receiving SOF/LED are still on treatment/pending evaluation.
![Page 8: RESULTS OF HEPATITIS C VIRUS (HCV) TREATMENT PROGRAM AMONG …regist2.virology-education.com/presentations/3... · In 2016 among new cases of HIV-infection (n=14 334) Viral Hepatitis](https://reader031.vdocuments.site/reader031/viewer/2022011912/5fa5eed0ef2ee675b9528dff/html5/thumbnails/8.jpg)
www.aph.org.uaStep 1. Sharing information on
the Project via NGOs,
communities and medical staff;
referrals to HCV diagnostic
Step 2. Case-manager informs
potential patients from key groups
about enrollment criteria and
refers patients to a doctor Step 3. A doctor
conditions a list of
examinations required to
take enrollment decision
Step 5.
Selection of the
treatment
regimen for
enrolled patients
Step 6. Social support
provided by a case
manager;
3 sessions on re-
infection prevention
Step 7.
Laboratory
monitoring of
treatment
END of
TREATMENT
MD
Team
Step 8. Treatment
success evaluation
(HCV VL test at
W12 after end of
treatment) Dia
gnostic
s
Step 4.Multi-disciplinary
team consisting of a
doctor, a nurse and a
social worker takes joint
decision on patients
enrollment (MDT)
Community-based HCV Treatment Model
![Page 9: RESULTS OF HEPATITIS C VIRUS (HCV) TREATMENT PROGRAM AMONG …regist2.virology-education.com/presentations/3... · In 2016 among new cases of HIV-infection (n=14 334) Viral Hepatitis](https://reader031.vdocuments.site/reader031/viewer/2022011912/5fa5eed0ef2ee675b9528dff/html5/thumbnails/9.jpg)
www.aph.org.ua
Multidisciplinary Approach to Patient Oriented
Integrated Services
Patient
Doctor & Nurse
Consultations
Diagnostics
Administering treatment
Dispensing medicines
Clinical monitoring
Laboratory monitoring
Social Support at the Time of Treatment
Counseling
Scheduling visits to doctors
Prevention of re-infection sessions
Linking ART and OST (if necessary)
Multidisciplinary team
(MDT) consisting of a doctor,
a nurse and social worker takes joint
decision on patients enrollment
Case
Manager
![Page 10: RESULTS OF HEPATITIS C VIRUS (HCV) TREATMENT PROGRAM AMONG …regist2.virology-education.com/presentations/3... · In 2016 among new cases of HIV-infection (n=14 334) Viral Hepatitis](https://reader031.vdocuments.site/reader031/viewer/2022011912/5fa5eed0ef2ee675b9528dff/html5/thumbnails/10.jpg)
www.aph.org.ua
Interventions of HCV Re-infection Prevention (3 sections)
1. Referral, linkage and access to harm reduction program:
• Needles, Syringes Program (NSP)
• Opioid Substitution Treatment (OST)
• Condoms Distribution (CD)
2. Safe health behavior intervention aimed at raising awareness on HCV risk factors adherence to treatment:
• Informational sessions on HCV transmission
• Breaking myths about HCV treatment
• Filling in HCV awareness gaps 3. Communications with relatives, partners, friends
• Informational sessions on HCV transmission
![Page 11: RESULTS OF HEPATITIS C VIRUS (HCV) TREATMENT PROGRAM AMONG …regist2.virology-education.com/presentations/3... · In 2016 among new cases of HIV-infection (n=14 334) Viral Hepatitis](https://reader031.vdocuments.site/reader031/viewer/2022011912/5fa5eed0ef2ee675b9528dff/html5/thumbnails/11.jpg)
www.aph.org.uawww.aph.org.ua
Retaining in care among PWID (n=1512)
• Retaining in care level among PWID shown by our Treatment Project is 98.4%
• Only 1.6% (n=24) PWID patients enrolled terminated treatment:• 10 patients suffered serious adverse events (4 were reenrolled on
treatment);
• 8 patients refused to continue treatment (1 was reenrolled on treatment);
• 4 patients died;
• 1 patient on SOF+RBV 24W had detectable HCV VL at W12
• 1 patient discovered cervical cancer, was transferred to oncology center (was reenrolled on treatment)
![Page 12: RESULTS OF HEPATITIS C VIRUS (HCV) TREATMENT PROGRAM AMONG …regist2.virology-education.com/presentations/3... · In 2016 among new cases of HIV-infection (n=14 334) Viral Hepatitis](https://reader031.vdocuments.site/reader031/viewer/2022011912/5fa5eed0ef2ee675b9528dff/html5/thumbnails/12.jpg)
www.aph.org.ua
HCV Treatment Project Findings
o Treatment of PWID and retaining them on care continues to be a challenge
o Multidisciplinary approach with high attention to social support shows itself as a highly
effective service model of HCV treatment for PWID
o Treatment of PWID with DAAs provided by multidisciplinary teams with enhanced social
support showed
✓ PWID high adherence to HCV treatment
✓ PWID high treatment success rates
✓ similar effectiveness of treatment among PWID-patients with HIV/HCV co-
infection and HCV mono-infection
o HCV treatment scale-up with DAA in Ukraine and other countries in the region will require
substantial price reductions inmedications, governmental commitment and organized efforts of
stakeholders to overcome structural and program barriers
![Page 13: RESULTS OF HEPATITIS C VIRUS (HCV) TREATMENT PROGRAM AMONG …regist2.virology-education.com/presentations/3... · In 2016 among new cases of HIV-infection (n=14 334) Viral Hepatitis](https://reader031.vdocuments.site/reader031/viewer/2022011912/5fa5eed0ef2ee675b9528dff/html5/thumbnails/13.jpg)
www.aph.org.ua
Thank You5 Dilova st., building 10A, 9th floor
03680 Kyiv, Ukraine
Tel.: (+380 44) 490-5485
Fax: (+380 44) 490-5489
e-mail: [email protected]
http://aph.org.ua
www.aph.org.ua
www.aph.org.ua